19,362 Shares in Artivion, Inc. $AORT Acquired by Penn Capital Management Company LLC

Key Points

• Penn Capital Management Company LLC acquired 19,362 shares of Artivion, Inc. for approximately $476,000, adding to the trend of institutional investment in the stock.
• Artivion's stock is currently trading at $44.81, having increased by 3.9%, with a market capitalization of $2.11 billion.
• The company recently reported earnings of $0.24 per share, exceeding estimates, with quarterly revenue rising by 15.3% year-over-year to $112.97 million.

Penn Capital Management Company LLC purchased a new position in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 19,362 shares of the company's stock, valued at approximately $476,000.

A number of other institutional investors and hedge funds have also modified their holdings of AORT. Wells Fargo & Company MN raised its stake in shares of Artivion by 22.1% during the fourth quarter. Wells Fargo & Company MN now owns 34,823 shares of the company's stock worth $996,000 after buying an additional 6,299 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Artivion during the fourth quarter worth approximately $275,000. Barclays PLC raised its stake in shares of Artivion by 1.2% during the fourth quarter. Barclays PLC now owns 71,697 shares of the company's stock worth $2,051,000 after buying an additional 820 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Artivion during the fourth quarter worth approximately $4,771,000. Finally, MetLife Investment Management LLC grew its holdings in Artivion by 7.4% during the fourth quarter. MetLife Investment Management LLC now owns 24,103 shares of the company's stock valued at $689,000 after purchasing an additional 1,671 shares during the period. 86.37% of the stock is owned by institutional investors.

Artivion Stock Up 3.9%

Artivion stock opened at $44.8140 on Friday. The stock has a market capitalization of $2.11 billion, a PE ratio of -106.70 and a beta of 1.64. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $45.07. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The company has a 50 day moving average of $33.65 and a 200-day moving average of $28.85.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.13. The company had revenue of $112.97 million during the quarter, compared to analysts' expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company's revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AORT. Stifel Nicolaus boosted their price objective on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a report on Friday, August 8th. JMP Securities boosted their price objective on shares of Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a report on Friday, August 8th. LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and boosted their price objective for the company from $32.00 to $38.80 in a report on Wednesday, August 13th. Canaccord Genuity Group boosted their price objective on shares of Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 8th. Finally, Needham & Company LLC boosted their price objective on shares of Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $40.63.

Insider Activity at Artivion

In other news, SVP Marshall S. Stanton sold 26,132 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $28.44, for a total value of $743,194.08. Following the sale, the senior vice president owned 79,200 shares of the company's stock, valued at $2,252,448. The trade was a 24.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John E. Davis sold 10,802 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the sale, the insider directly owned 208,778 shares in the company, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 96,538 shares of company stock worth $3,444,651 over the last ninety days. 7.60% of the stock is owned by corporate insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.